Tekmira in 1-for-5 stock consolidation

Tekmira Pharmaceuticals (TSX:TKM) is consolidating its common stock on a one-for-five basis in order to meet listing requirements on the Nasdaq Stock Market, with the goal of listing on Nasdaq the week of Nov. 15, 2010. Tekmira will have 10,337,414 common shares outstanding after the consolidation. The stock will begin trading on a post-consolidated basis [...]

Canadians’ data heading to ASCO

Versant Partners analyst Doug Loe has compiled a list of six biotech companies that will have data presented at the American Society of Clinical Oncology meeting on June 4 to 8.  He expects: · AEterna Zentaris (NASDAQ:AEZS; TSX:AEZ) to report final data from its 43-patient Phase 2 advanced ovarian cancer trial with its AEZS-108 drug, [...]

Tekmira reports on protection against deadly Ebola virus

Tekmira Pharmaceuticals (TSX:TKM) has published a series of studies in The Lancet demonstrating the ability of an RNA-interference therapeutic using Tekmira’s SNALP lipid nanoparticle delivery technology to protect non-human primates from Ebola virus, a highly contagious and lethal human infectious disease. “These very striking data are the first demonstration that RNAi is efficacious in an [...]

Tekmira plans NASDAQ listing

Tekmira Pharmaceuticals (TSX:TKM) plans to apply to list its common shares on the Nasdaq stock market in the next few months. “Many of our peers have securities listed in the U.S. and we believe doing so is a logical step in the evolution of Tekmira to be appropriately valued as a leader in the RNA [...]

Tekmira and Pfizer in research collaboration

Tekmira Pharmaceuticals (TSX:TKM) has initiated a new research collaboration with Pfizer to evaluate Tekmira’s stable nucleic acid-lipid particle (SNALP) technology to deliver small interfering RNA molecules provided by Pfizer (NYSE:PFE). This is Tekmira’s first formal research collaboration with Pfizer. Tekmira will be responsible for preparing the SNALP formulations and Pfizer will evaluate the formulations in [...]

Tekmira’s leading RNAi platform ready for prime time

As a global leader in the emerging field of RNA interference (RNAi), which holds the potential of revolutionizing medicine with new therapeutics, upstart Tekmira Pharmaceuticals (TSX:TKM) is at the precipice of confirming that the highly touted science works in humans. “We really are at the crux,” CEO Dr. Mark Murray says in an exclusive interview [...]

Tekmira ups potency of delivery platform

New research published in the journal Nature Biotechnology has disclosed that Tekmira Pharmaceuticals (TSX:TKM) has developed a new lipid component that provides a ten-fold improvement in the potency of its SNALP delivery platform. “This work advances Tekmira’s leadership position in the delivery of RNA interference therapeutics and supports our strategy of expanding the tremendous potential [...]

Tekmira readying release of clinical data

Tekmira Pharmaceuticals (TSX: TKM) is on track to release data from its highly anticipated Phase 1 clinical trial for its lead product ApoB SNALP in the first quarter next year, CEO Dr. Mark Murray said in the third quarter report. The Vancouver-based company has leading edge technology in the area of RNA-interference and ApoB SNALP [...]

In conversation with Maher Yaghi

As Desjardins Securities’ healthcare and biotech analyst for the past five years, Maher Yaghi has gained a wide following with a blunt, tell-it-like-it-is approach to covering a sector that has struggled to win the hearts and minds of investors in recent years.  His early research and “buy” recommendations on Theratechnologies and Paladin Labs established his [...]